Cancer Chemotherapy and Biotherapy
Principles and Practice
5th Edition
Published on 16. November 2010
Book
Hardback
848 pages
978-1-60547-431-1 (ISBN)
Description
Updated to include the newest drugs and those currently in development, Cancer Chemotherapy and Biotherapy, Fifth Edition is a comprehensive reference on the preclinical and clinical pharmacology of anticancer agents. Organized by drug class, the book provides the latest information on all drugs and biological agents-their mechanisms of action, interactions with other agents, toxicities, side effects, and mechanisms of resistance. Chapters emphasize pharmacology and mechanisms of action at the molecular and cellular levels, followed by clinical activity and toxicity, both acute and delayed. The authors explain the rationale for use of drugs in specific schedules and combinations and offer guidelines for dose adjustment in particular situations.
This edition's introduction includes timely information on general strategies for drug usage, the science of drug discovery and development, economic and regulatory aspects of cancer drug development, and principles of pharmacokinetics. Eight new chapters have been added and more than twenty have been significantly revised.
A companion website includes the fully searchable text and an image bank.
Updated to include the newest drugs and those currently in development, <b>Cancer Chemotherapy and Biotherapy, Fifth Edition</b> is a comprehensive reference on the preclinical and clinical pharmacology of anticancer agents. Organized by drug class, the book provides the latest information on all drugs and biological agents-their mechanisms of action, interactions with other agents, toxicities, side effects, and mechanisms of resistance. Chapters emphasize pharmacology and mechanisms of action at the molecular and cellular levels, followed by clinical activity and toxicity, both acute and delayed. The authors explain the rationale for use of drugs in specific schedules and combinations and offer guidelines for dose adjustment in particular situations.
This edition's introduction includes timely information on general strategies for drug usage, the science of drug discovery and development, economic and regulatory aspects of cancer drug development, and principles of pharmacokinetics. Eight new chapters have been added and more than twenty have been significantly revised.
A companion website includes the fully searchable text and an image bank.
This edition's introduction includes timely information on general strategies for drug usage, the science of drug discovery and development, economic and regulatory aspects of cancer drug development, and principles of pharmacokinetics. Eight new chapters have been added and more than twenty have been significantly revised.
A companion website includes the fully searchable text and an image bank.
Updated to include the newest drugs and those currently in development, <b>Cancer Chemotherapy and Biotherapy, Fifth Edition</b> is a comprehensive reference on the preclinical and clinical pharmacology of anticancer agents. Organized by drug class, the book provides the latest information on all drugs and biological agents-their mechanisms of action, interactions with other agents, toxicities, side effects, and mechanisms of resistance. Chapters emphasize pharmacology and mechanisms of action at the molecular and cellular levels, followed by clinical activity and toxicity, both acute and delayed. The authors explain the rationale for use of drugs in specific schedules and combinations and offer guidelines for dose adjustment in particular situations.
This edition's introduction includes timely information on general strategies for drug usage, the science of drug discovery and development, economic and regulatory aspects of cancer drug development, and principles of pharmacokinetics. Eight new chapters have been added and more than twenty have been significantly revised.
A companion website includes the fully searchable text and an image bank.
More details
Edition
5th edition
Language
English
Place of publication
Philadelphia
United States
Target group
Professional and scholarly
Product notice
Cloth over boards
Dimensions
Height: 276 mm
Width: 213 mm
Weight
2177 gr
ISBN-13
978-1-60547-431-1 (9781605474311)
Copyright in bibliographic data and cover images is held by Nielsen Book Services Limited or by the publishers or by their respective licensors: all rights reserved.
Schweitzer Classification
Other editions
New editions
Bruce A. Chabner | Dan L. Longo
Cancer Chemotherapy, Immunotherapy, and Biotherapy
Book
08/2024
7th Edition
WOLTERS KLUWER HEALTH
€257.50
Available immediately
Bruce A. Chabner | Dan L. Longo
Cancer Chemotherapy, Immunotherapy and Biotherapy
Book
10/2018
6th Edition
Lippincott Williams and Wilkins
€333.32
Article exhausted; check for reprint
Previous edition
Book
11/2005
4th Edition
Lippincott Williams and Wilkins
€211.31
Article exhausted; check for reprint
Content
Section 1: BASIC PRINCIPLES OF CANCER TREATMENT
1: Clinical Strategies for Cancer Treatment: The Role of Drugs
Bruce Chabner
2: Target Identification and Drug Discovery
Ed Sausville
3: Clinical Drug Development and Approval for Marketing
Thomas Roberts
4: Principles of Pharmacokinetics
Jerry Collins
5: Special Aspects of Brain Tumor Chemotherapy
Jeffrey Supko & Tracy Batchelor
6: Pharmacogenetics
Howard McLeod
7: Barriers to Drug Delivery
Brendan Curti
Section 2: CYTOTOXIC AGENTS
8: Antifolates
Carmen Allegra & Bruce Chabner
9: Fluoro-pyrimidines
David Ryan, Bruce Chabner & Ray Wadlow
10: Cytidine Analogues
David Ryan & Bruce Chabner
11: Purine Analogues
Ken Hande
12: Hydroxyurea
Bruce Chabner
13: Antimitotic Drugs
Ross Donehower
14: Alkylating Agents (Including Methylating Agents)
Stan Gerson & Henry Friedman
15: Platinum Analogues
Ed Reed
16: Antitumor Antibiotics (Including Bleomycin)
Bruce Chabner
17: Topoisomerase I Inhibitors
Alex Spaareboom & William Zamboni
18: Topoisomerase II Inhibitors: Anthracyclines
Jim Doroshow
19: Topoisomerase II Inhibitors: Etoposide, Teniposide
George Hartman & Yves Pommier
20: L-Asparaginase
Bruce Chabner & Alison Friedmann
Section 3: MOLECULARLY TARGETED THERAPIES
21: Proteosome Inhibitors
Orhan Sezar
22: HDAC Inhibitors
Susan Bates
23: Differentiating Agents (Retinoids)
Bruce Chabner
24: Arsenic Trioxide
Bruce Chabner
25: Monoclonal Antibodies: Discovery & Development
David Scheinberg
26: Anti-angiogenic Agents (Including MonAB)
William Gradishar & Kari Wisinski
27: Anti-EGFR Therapies (Including MonAB)
Lecia Sequist & Joel Neal
28: Anti-her 2 Therapies
Eric Winer
29: Intracellular Signal Inhibitors (bcr-abl)
Bruce Chabner & Jeffrey Barnes
30: Signal Transduction Inhibitors in Development
Jeff Clark
31: Inhibitors of the PI3k Pathway & Mitotic Kinase
Percy Ivy
Section 4: IMMUNOLOGIC AGENTS
32: Interferon and Cytokines
David McDermott
33: Vaccines
Robert G. Fenton
34: Adoptive Cellular Therapies
Cassian Yee
35: Immuno-modulatory Drugs (IMIDS, Anti-CTLA4)
Paul Richardson et al.
Section 5: HORMONAL THERAPY
36: Hormonal Therapy of Breast Cancer
Beverly Moy & Paul Goss
37: GNRH Agonists and Anti-Androgens
Richard Lee
Section 6: SUPPORTIVE CARE
38: Pain Management in Cancer Patients
Paul Glare
39: Colony Stimulating Factors
Gary Lyman
40: Anti-nausea Medications
Ian Olver
41: Bone Loss Modulators
Matthew Smith
42: Intravenous Access and Catheter Management
Rachel Rosovsky
Section 7: SURVIVORSHIP
43: Monitoring for Late Side Effects of Chemotherapy
Richard Schilsky, Charles Erlichman & Brian Costello
1: Clinical Strategies for Cancer Treatment: The Role of Drugs
Bruce Chabner
2: Target Identification and Drug Discovery
Ed Sausville
3: Clinical Drug Development and Approval for Marketing
Thomas Roberts
4: Principles of Pharmacokinetics
Jerry Collins
5: Special Aspects of Brain Tumor Chemotherapy
Jeffrey Supko & Tracy Batchelor
6: Pharmacogenetics
Howard McLeod
7: Barriers to Drug Delivery
Brendan Curti
Section 2: CYTOTOXIC AGENTS
8: Antifolates
Carmen Allegra & Bruce Chabner
9: Fluoro-pyrimidines
David Ryan, Bruce Chabner & Ray Wadlow
10: Cytidine Analogues
David Ryan & Bruce Chabner
11: Purine Analogues
Ken Hande
12: Hydroxyurea
Bruce Chabner
13: Antimitotic Drugs
Ross Donehower
14: Alkylating Agents (Including Methylating Agents)
Stan Gerson & Henry Friedman
15: Platinum Analogues
Ed Reed
16: Antitumor Antibiotics (Including Bleomycin)
Bruce Chabner
17: Topoisomerase I Inhibitors
Alex Spaareboom & William Zamboni
18: Topoisomerase II Inhibitors: Anthracyclines
Jim Doroshow
19: Topoisomerase II Inhibitors: Etoposide, Teniposide
George Hartman & Yves Pommier
20: L-Asparaginase
Bruce Chabner & Alison Friedmann
Section 3: MOLECULARLY TARGETED THERAPIES
21: Proteosome Inhibitors
Orhan Sezar
22: HDAC Inhibitors
Susan Bates
23: Differentiating Agents (Retinoids)
Bruce Chabner
24: Arsenic Trioxide
Bruce Chabner
25: Monoclonal Antibodies: Discovery & Development
David Scheinberg
26: Anti-angiogenic Agents (Including MonAB)
William Gradishar & Kari Wisinski
27: Anti-EGFR Therapies (Including MonAB)
Lecia Sequist & Joel Neal
28: Anti-her 2 Therapies
Eric Winer
29: Intracellular Signal Inhibitors (bcr-abl)
Bruce Chabner & Jeffrey Barnes
30: Signal Transduction Inhibitors in Development
Jeff Clark
31: Inhibitors of the PI3k Pathway & Mitotic Kinase
Percy Ivy
Section 4: IMMUNOLOGIC AGENTS
32: Interferon and Cytokines
David McDermott
33: Vaccines
Robert G. Fenton
34: Adoptive Cellular Therapies
Cassian Yee
35: Immuno-modulatory Drugs (IMIDS, Anti-CTLA4)
Paul Richardson et al.
Section 5: HORMONAL THERAPY
36: Hormonal Therapy of Breast Cancer
Beverly Moy & Paul Goss
37: GNRH Agonists and Anti-Androgens
Richard Lee
Section 6: SUPPORTIVE CARE
38: Pain Management in Cancer Patients
Paul Glare
39: Colony Stimulating Factors
Gary Lyman
40: Anti-nausea Medications
Ian Olver
41: Bone Loss Modulators
Matthew Smith
42: Intravenous Access and Catheter Management
Rachel Rosovsky
Section 7: SURVIVORSHIP
43: Monitoring for Late Side Effects of Chemotherapy
Richard Schilsky, Charles Erlichman & Brian Costello